Role of immunotherapy in gastroesophageal cancer with liver metastasis

The role of immune checkpoint inhibitors for patients with gastroesophageal cancer with liver metastasis remains unclear. Our objective was to investigate whether immune checkpoint inhibitors are beneficial in patients with gastroesophageal cancer with liver metastasis. We searched PubMed, Embase, E...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI cancer spectrum 2024-11, Vol.8 (6)
Hauptverfasser:	Bawek, Sawyer, Ramesh, Mrinalini, Gurusinghe, Sayuri, Aijaz, Ali, Attwood, Kristopher, Hossein-Javaheri, Nariman, Mukherjee, Sarbajit
Format:	Artikel
Sprache:	eng
Schlagworte:	Brief Communications Clinical Trials, Phase III as Topic Esophageal Neoplasms - drug therapy Esophageal Neoplasms - mortality Esophageal Neoplasms - pathology Esophageal Neoplasms - therapy Humans Immune Checkpoint Inhibitors - therapeutic use Immunotherapy Liver Neoplasms - drug therapy Liver Neoplasms - mortality Liver Neoplasms - secondary Progression-Free Survival Proportional Hazards Models Randomized Controlled Trials as Topic Stomach Neoplasms - drug therapy Stomach Neoplasms - mortality Stomach Neoplasms - pathology Stomach Neoplasms - therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The role of immune checkpoint inhibitors for patients with gastroesophageal cancer with liver metastasis remains unclear. Our objective was to investigate whether immune checkpoint inhibitors are beneficial in patients with gastroesophageal cancer with liver metastasis. We searched PubMed, Embase, European Society for Medical Oncology, and American Society of Clinical Oncology meeting abstracts for phase 3 randomized clinical trials testing immune checkpoint inhibitors in metastatic/advanced gastroesophageal cancer from 2017 to 2023. Seven studies were included. Overall survival was similar among all patients (hazard ratio [HR] = 0.72 [95% confidence interval (CI) = 0.67 to 0.77], P
ISSN:	2515-5091 2515-5091
DOI:	10.1093/jncics/pkae105